Three lines of targeted therapy for metastatic renal cell carcinoma (mRCC): A viable strategy?
Tomas Buchler
Honoraria - Bayer; Pfizer
Zbynek Bortlicek
No relevant relationships to disclose
Alexandr Poprach
No relevant relationships to disclose
Katerina Kubackova
Honoraria - Novartis
Other Remuneration - Novartis
Igor Kiss
Consultant or Advisory Role - Bayer
Milada Zemanova
No relevant relationships to disclose
Ondrej Fiala
No relevant relationships to disclose
Jitka Abrahamova
No relevant relationships to disclose
Bohuslav Melichar
Consultant or Advisory Role - Novartis
Honoraria - Novartis
Research Funding - Novartis